GoodRx Holdings, Inc. (NASDAQ:GDRX) Receives $3.81 Average Target Price from Analysts

GoodRx Holdings, Inc. (NASDAQ:GDRX) has earned a consensus recommendation of “Hold” from the fifteen ratings firms that are currently covering the stock, MarketBeat.com reports. Three investment analysts have rated the stock with a sell rating, seven have given a hold rating and five have assigned a buy rating to the company. The average 12 month price target among analysts that have updated their coverage on the stock in the last year is $3.8125.

GDRX has been the subject of several research analyst reports. The Goldman Sachs Group reiterated a “neutral” rating and issued a $3.50 price objective on shares of GoodRx in a research report on Friday, May 8th. Weiss Ratings lowered GoodRx from a “sell (d+)” rating to a “sell (d)” rating in a research report on Wednesday, May 20th. Citigroup boosted their price objective on GoodRx from $3.50 to $4.00 and gave the company a “buy” rating in a research report on Thursday, May 14th. Mizuho cut their target price on GoodRx from $4.00 to $3.00 and set a “neutral” rating on the stock in a research note on Friday, February 27th. Finally, Leerink Partners restated an “outperform” rating and issued a $3.00 target price on shares of GoodRx in a research note on Thursday, February 26th.

GoodRx Price Performance

Shares of GDRX opened at $2.65 on Friday. The company has a debt-to-equity ratio of 0.78, a quick ratio of 1.47 and a current ratio of 1.47. The stock has a 50 day simple moving average of $2.44 and a 200 day simple moving average of $2.49. GoodRx has a 52-week low of $1.77 and a 52-week high of $5.81. The firm has a market capitalization of $907.81 million, a PE ratio of 44.17, a P/E/G ratio of 1.23 and a beta of 1.61.

GoodRx (NASDAQ:GDRX) last issued its quarterly earnings data on Wednesday, May 6th. The company reported $0.07 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.07. GoodRx had a return on equity of 7.90% and a net margin of 2.61%.The business had revenue of $194.01 million during the quarter, compared to analyst estimates of $185.40 million. During the same period in the previous year, the firm earned $0.09 EPS. GoodRx’s quarterly revenue was down 4.4% compared to the same quarter last year. Sell-side analysts predict that GoodRx will post 0.17 EPS for the current fiscal year.

Institutional Investors Weigh In On GoodRx

Several institutional investors have recently bought and sold shares of the company. Essential Partners LLC lifted its stake in GoodRx by 375.4% in the 1st quarter. Essential Partners LLC now owns 14,304 shares of the company’s stock valued at $28,000 after acquiring an additional 11,295 shares in the last quarter. Amundi bought a new stake in GoodRx in the 1st quarter valued at approximately $37,000. Renaissance Technologies LLC lifted its stake in GoodRx by 1.5% in the 1st quarter. Renaissance Technologies LLC now owns 3,259,738 shares of the company’s stock valued at $6,389,000 after acquiring an additional 48,800 shares in the last quarter. Wealthfront Advisers LLC bought a new stake in GoodRx in the 1st quarter valued at approximately $55,000. Finally, DGS Capital Management LLC bought a new stake in GoodRx in the 1st quarter valued at approximately $48,000. Institutional investors own 63.77% of the company’s stock.

GoodRx Company Profile

GoodRx Holdings, Inc (NASDAQ: GDRX) operates a digital healthcare platform designed to help consumers compare prescription drug prices at retail pharmacies across the United States. Through its website and mobile applications, GoodRx aggregates pricing and discount information from a wide network of pharmacies, enabling users to access coupons and savings programs on both generic and brand-name medications. The platform also features price transparency tools that inform patients about cost variations and available discounts to alleviate the financial burden of prescription medications.

In addition to its core drug pricing service, GoodRx offers telehealth services under the GoodRx Care brand, providing virtual consultations for a range of non-emergency conditions and prescription needs.